BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
BTAIBioXcel Therapeutics(BTAI) Newsfilter·2024-02-06 20:00

BioXcel Therapeutics - BioXcel Therapeutics宣布完成BXCL701与KEYTRUDA联合治疗转移性胰腺导管腺癌的安全性试验患者招募[1] - BXCL701是一种口服的先天免疫激活剂，旨在引发肿瘤微环境的炎症，增强检查点抑制剂的活性[3] - BXCL701在前列腺癌和晚期实体肿瘤治疗中显示出潜在疗效，已获得美国食品和药物管理局四种孤儿药物认定[5]